IGMS IGM Biosciences: Multiplikator Forward P/S
IGM Biosciences, Inc. (IGMS) has completely shifted its strategic direction, pivoting away from oncology to focus on combating autoimmune pathologies. The current strategy is based on the implementation of IgM antibodies and support from Sanofi, which is reflected in the forward P/S valuation, where 0.30 represents the current metric. Business value growth now relies on progress in clinical trials and updated partnership data.
Rincian metrik komprehensif lan analitis IGM Biosciences (IGMS)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas IGM Biosciences, Inc.|IGMS - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal IGM Bio|IGMS - Utang perusahaan|Utang-utang marang kapitalisasi buku IGM Bio|IGMS - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan IGM Biosciences|Likuiditas cepet igmbio.com
- rincian asil keuangan lan kelipatan valuasi:
IGMS - Asil keuangan resik|Proyeksi bathi mangsa ngarep IGM Biosciences, Inc.|IGMS - Koefisien rega marang bathi|Pangali Forward P/E igmbio.com|IGMS - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA IGM Biosciences, Inc.|IGMS - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan IGM Biosciences|IGMS - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan igmbio.com|IGMS - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep IGM Biosciences, Inc.
- data pendapatan lan penerimaan dodolan:
Ringkesan analitik perusahaan:IGM Biosciences Inc. IGMS
Forward P/S measures an asset's market value relative to expected sales volume, allowing for an assessment of price volatility amplitude during external shocks. Analysis of the forward P/S chart for IGM Biosciences, Inc. (IGMS) reveals the capitalization's sensitivity to revenue growth rates, which is critical for IGM Biosciences, Inc. (IGMS) during the downsizing of its oncology division and the transition to organic R&D tests in partnership with Sanofi.
Analisis perusahaan pesaing
Multiplikator Forward P/S ARGX (argenx.com)|BioNTech Group (BNTX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ABIVAX - Multiplikator Forward P/S|ADMA - Multiplikator Forward P/S|Protagonist (PTGX) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Immunovant Inc|Rasio rega marang prakiraan pendapatan Kiniksa Pharmaceuticals|Grifols Group (GRFS) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Adaptive Biotechnologies Corp (ADPT)|Rasio rega marang prakiraan pendapatan CLDX (Celldex Therapeutics)|Rasio rega marang prakiraan pendapatan Aurinia Pharma AUPH|Rega forward marang dodolan BCRX|VERA: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan DNTH (Dianthus Therapeutics)|Pharvaris N.V. (PHVS) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep AbCellera Biologics (ABCL)|TRML (Tourmaline Bio Inc) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan PGEN (Intrexon)|Multiplikator forward rega marang pendapatan PHAR (Pharming)|NKTR (Nektar) - Rega forward marang dodolan|Multiplikator Forward P/S UPB (upstreambio.com)|ZBIO (Zenas Biopharma Inc) - Rega mangsa ngarep marang pendapatan|IMNM - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Gossamer Bio Inc GOSS|KALV: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Septerna Pharma|PVLA (Pieris Corp) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan SVRA|Multiplikator Forward P/S RIGL|Multiplikator forward rega marang pendapatan AnaptysBio Corp ANAB|Astria Therapeutics Inc - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake enGene Holdings Inc. (ENGN)|RAPT Therapeutics Inc. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Aerovate Therapeutics, Inc.|ACRS (Aclaris Therapeutics) - Multiplikator forward rega marang pendapatan|KYTX: Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan Tiziana Life Sciences|Cabaletta Bio, Inc (CABA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan VTYX (Ventyx Biosciences)|Rasio kapitalisasi marang dodolan sing dikarepake theratech.com|Multiplikator Forward P/S AVTX (Avalo Therapeutics, Inc.)|Multiplikator Forward P/S Eledon Pharmaceuticals Inc. ELDN|AGEN: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan CLYM (Climb Bio, Inc)|ZURA: Multiplikator Forward P/S|aTyr Pharma, Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Adagene Inc.|IMA: Rega forward marang dodolan|Multiplikator Forward P/S STTK|Multiplikator forward rega marang pendapatan Equillium Bio EQ|Rasio rega marang prakiraan pendapatan Connect Biopharma CNTB|IMUX - Multiplikator forward rega marang pendapatan|ATRA - Rasio rega marang prakiraan pendapatan|InflaRx NV (IFRX) - Multiplikator forward rega marang pendapatan|XFOR (X4 Pharmaceuticals Inc.) - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Adicet Bio Inc. (ACET)|Rasio rega marang prakiraan pendapatan celularity.com|Multiplikator forward rega marang pendapatan inmunebio.com (INMB)|Rasio rega marang prakiraan pendapatan Barinthus Biotherapeutics PLC (BRNS)|Rasio kapitalisasi marang dodolan sing dikarepake Kezar Life Sciences Inc.|SAB Biotherapeutics, Inc - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Akari Therapeutics, Plc (AKTX)|ENLV: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan QTTB (q32bio.com)|GeoVax Labs Inc (GOVX) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Edesa|Rasio rega marang prakiraan pendapatan iBio, Inc.|Multiplikator forward rega marang pendapatan carismatx.com (CARM)|Multiplikator Forward P/S XTLB|Multiplikator forward rega marang pendapatan Bolt Bio BOLT|Multiplikator Forward P/S HCWB (HCW Biologics)|APVO: Kapitalisasi marang prakiraan pendapatan|AIM - Rasio rega marang prakiraan pendapatan|ADTX - Multiplikator Forward P/S|GRI Bio (GRI) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan XORTX Therapeutics|Rasio rega marang prakiraan pendapatan Vyome Therapeutics|Kapitalisasi marang prakiraan pendapatan REVB (Revelation Biosciences, Inc.)|Multiplikator Forward P/S INDP|Multiplikator forward rega marang pendapatan Scinai Immunotherapeutics SCNI|Multiplikator Forward P/S CALI (CalciMedica)|AFMD - Multiplikator forward rega marang pendapatan|ALLK: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake HOOKIPA Pharma HOOK|ITOS (iTeos Therapeutics, Inc.) - Multiplikator forward rega marang pendapatan|Ocean Biomedical Corp (OCEA) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan TC BioPharm (Holdings) PLC|Multiplikator Forward P/S thirdharmonicbio.com
